BioCentury | Sep 2, 2020
Deals

NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

...By Virginia Li, Associate Editor With this week’s addition of a NASH therapy from Novartis, Boston Pharmaceuticals is well...
...Robert Armstrong when they launched the in-licensing play with $600 million in 2015.The deal gives Boston Pharmaceuticals Inc....
...fits into our portfolio in the sense that it meets those characteristics.”Gurnet Point Capital launched Boston Pharmaceuticals...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...survival. Next steps include mechanistic studies of DGAT1 in GBM. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Boston Pharmaceuticals Inc....
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...is SVP, head of Canada, Europe, Middle East and Africa at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Boston Pharmaceuticals Inc....
...care. He was SVP of business development and VA/integrated healthcare systems at MDxHealth S.A. (Euronext:MDXH). BioCentury Staff Boston Pharmaceuticals Inc. CytomX...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...are in development.” She said it is roughly 10 times more potent than BOS-172722 from Boston Pharmaceuticals Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...at OncoMed Pharmaceuticals Inc., which Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO) acquired in April 2018. Boston Pharmaceuticals Inc....
...is an advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape Bio Inc. Boston Pharmaceuticals Inc. MaxCyte...
BioCentury | Oct 11, 2019
Preclinical News

Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR

...compound, which originated at ICR, is in Phase I testing for advanced solid tumors by Boston Pharmaceuticals Inc....
BioCentury | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

...steps include testing undisclosed small molecule DGAT1 inhibitors in models of MS. GlaxoSmithKline plc and Boston Pharmaceuticals Inc....
BioCentury | Oct 5, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

...Phase III plans for companies that might want to purchase them following Phase II testing. Boston Pharmaceuticals...
...LSE:GSK; NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Boston Pharmaceuticals Inc., Cambridge, Mass. Business: Pharmaceuticals Sandi Wong GSK3008356 GSK3183475 GSK3352589 IID572 LYS228 MAK181 Boston Pharmaceuticals Inc. GlaxoSmithKline...
BioCentury | Oct 3, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

...Phase III plans for companies that might want to purchase them following Phase II testing. Boston Pharmaceuticals...
...2015 with the intention of in-licensing a portfolio of 20-25 assets (see "Community Chorus" ). Sandi Wong Boston Pharmaceuticals Inc. GlaxoSmithKline...
BioCentury | Jun 26, 2018
Company News

Roche’s Kornowski joining Gurnet Point

...to Boston Pharmaceuticals Inc. (Cambridge, Mass.) with the intention of in-licensing a portfolio of 20-25 assets (see "Boston Pharmaceuticals...
Items per page:
1 - 10 of 15
BioCentury | Sep 2, 2020
Deals

NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

...By Virginia Li, Associate Editor With this week’s addition of a NASH therapy from Novartis, Boston Pharmaceuticals is well...
...Robert Armstrong when they launched the in-licensing play with $600 million in 2015.The deal gives Boston Pharmaceuticals Inc....
...fits into our portfolio in the sense that it meets those characteristics.”Gurnet Point Capital launched Boston Pharmaceuticals...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...survival. Next steps include mechanistic studies of DGAT1 in GBM. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Boston Pharmaceuticals Inc....
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...is SVP, head of Canada, Europe, Middle East and Africa at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Boston Pharmaceuticals Inc....
...care. He was SVP of business development and VA/integrated healthcare systems at MDxHealth S.A. (Euronext:MDXH). BioCentury Staff Boston Pharmaceuticals Inc. CytomX...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

...are in development.” She said it is roughly 10 times more potent than BOS-172722 from Boston Pharmaceuticals Inc....
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...at OncoMed Pharmaceuticals Inc., which Mereo BioPharma Group plc (LSE:MPH; NASDAQ:MREO) acquired in April 2018. Boston Pharmaceuticals Inc....
...is an advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape Bio Inc. Boston Pharmaceuticals Inc. MaxCyte...
BioCentury | Oct 11, 2019
Preclinical News

Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR

...compound, which originated at ICR, is in Phase I testing for advanced solid tumors by Boston Pharmaceuticals Inc....
BioCentury | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

...steps include testing undisclosed small molecule DGAT1 inhibitors in models of MS. GlaxoSmithKline plc and Boston Pharmaceuticals Inc....
BioCentury | Oct 5, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

...Phase III plans for companies that might want to purchase them following Phase II testing. Boston Pharmaceuticals...
...LSE:GSK; NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Boston Pharmaceuticals Inc., Cambridge, Mass. Business: Pharmaceuticals Sandi Wong GSK3008356 GSK3183475 GSK3352589 IID572 LYS228 MAK181 Boston Pharmaceuticals Inc. GlaxoSmithKline...
BioCentury | Oct 3, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

...Phase III plans for companies that might want to purchase them following Phase II testing. Boston Pharmaceuticals...
...2015 with the intention of in-licensing a portfolio of 20-25 assets (see "Community Chorus" ). Sandi Wong Boston Pharmaceuticals Inc. GlaxoSmithKline...
BioCentury | Jun 26, 2018
Company News

Roche’s Kornowski joining Gurnet Point

...to Boston Pharmaceuticals Inc. (Cambridge, Mass.) with the intention of in-licensing a portfolio of 20-25 assets (see "Boston Pharmaceuticals...
Items per page:
1 - 10 of 15